sj-pdf-3-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial

Supplemental material, sj-pdf-3-cep-10.1177_03331024221128250 for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial by Brad C Klein, Rosa Miceli, Lawrence Severt, Peter McAllister, Laszlo Mechtler, Jennifer McVige, Merle Diamond, Michael J Marmura, Hua Guo, Michelle Finnegan and Joel M Trugman in Cephalalgia